Status:
RECRUITING
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Anti Phospholipid Syndrome
Eligibility:
All Genders
Brief Summary
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (aPLs). However, large-...
Detailed Description
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks (CAPSTONE) is a national research network created to register patients with persistent aPLs. We aim at enrolling 2000 patients from a to...
Eligibility Criteria
Inclusion
- The presence of one or more of the antiphospholipid antibodies (aPL) tested according to the 2006 Sapporo APS clasification criteria, on two or more occasions at least 12 weeks apart:
Exclusion
- Patients refuse to participate;
- Unable to be followed.
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05230017
Start Date
October 1 2022
End Date
December 1 2026
Last Update
July 30 2024
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
2
Beijing Shunyi Hospital
Beijing, Beijing Municipality, China, 101300
3
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
4
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510150